Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Nov 21;24(23):16569.
doi: 10.3390/ijms242316569.

PEGylation of Terminal Ligands as a Route to Decrease the Toxicity of Radiocontrast Re6-Clusters

Affiliations

PEGylation of Terminal Ligands as a Route to Decrease the Toxicity of Radiocontrast Re6-Clusters

Aleksei S Pronin et al. Int J Mol Sci. .

Abstract

The development of novel radiocontrast agents, mainly used for the visualization of blood vessels, is still an emerging task due to the variety of side effects of conventional X-ray contrast media. Recently, we have shown that octahedral chalcogenide rhenium clusters with phosphine ligands-Na2H14[{Re6Q8}(P(C2H4COO)3)6] (Q = S, Se)-can be considered as promising X-ray contrast agents if their relatively high toxicity related to the high charge of the complexes can be overcome. To address this issue, we propose one of the most widely used methods for tuning the properties of proteins and peptides-PEGylation (PEG is polyethylene glycol). The reaction between the clusters and PEG-400 was carried out in acidic aqueous media and resulted in the binding of up to five carboxylate groups with PEG. The study of cytotoxicity against Hep-2 cells and acute toxicity in mice showed a twofold reduction in toxicity after PEGylation, demonstrating the success of the strategy chosen. Finally, the compound obtained has been used for the visualization of blood vessels of laboratory rats by angiography and computed tomography.

Keywords: PEGylation; X-ray contrast media; acute toxicity; angiography; computed tomography; cytotoxicity; octahedral chalcogenide rhenium cluster; phosphine.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Schematic representation of the esterification of the apical ligand of the cluster.
Figure 2
Figure 2
HR-ESI-MS spectra of the aqueous solutions of 1-PEG ((A), green) and 2-PEG ((B), pink) in positive mode (2+) and a simulation of PEGylated cluster forms (colored).
Figure 3
Figure 3
Cytotoxicity of 1-PEG (A) and 2-PEG (B) against Hep-2 cells in comparison with the corresponding initial clusters.
Figure 4
Figure 4
Survival rate of mice injected intravenously with 100 µL of 1-PEG (A) or 2-PEG (B) at different doses (n = 5).
Figure 5
Figure 5
Biodistribution of the rhenium in mice organs (dose = 350 mgRe kg−1) for 1-PEG (A) and 2-PEG (B) determined using ICP-OES.
Figure 6
Figure 6
Angiography (up) and X-ray computed tomography images (down) of SD (Sprague Dawley) rats obtained during the administration of 1-PEG (A,C) or 2-PEG (B,D) (dose = 325 mgRe kg−1). Contrasted vessels are marked with arrows.

References

    1. Röentgen W.C. On a New Kind of Rays. Phys. Med. Ges. Wurzburg. 1895;137:132–141.
    1. Koç M.M., Aslan N., Kao A.P., Barber A.H. Evaluation of X-ray Tomography Contrast Agents: A Review of Production, Protocols, and Biological Applications. Microsc. Res. Tech. 2019;82:812–848. doi: 10.1002/jemt.23225. - DOI - PubMed
    1. Aspelin P., Aubry P., Fransson S.-G., Strasser R., Willenbrock R., Lundkvist J. Cost-Effectiveness of Iodixanol in Patients at High Risk of Contrast-Induced Nephropathy. Am. Heart J. 2005;149:298–303. doi: 10.1016/j.ahj.2004.07.020. - DOI - PubMed
    1. Wisneski J.A., Gertz E.W., Dahlgren M., Muslin A. Comparison of Low Osmolality Ionic (Ioxaglate) versus Nonionic (Iopamidol) Contrast Media in Cardiac Angiography. Am. J. Cardiol. 1989;63:489–495. doi: 10.1016/0002-9149(89)90325-1. - DOI - PubMed
    1. Andersen P.E., Bolstad B., Berg K.J., Justesen P., Thayssen P., Kloster Y.F. Iodixanol and Ioxaglate in Cardioangiography: A Double-Blind Randomized Phase III Study. Clin. Radiol. 1993;48:268–272. doi: 10.1016/S0009-9260(05)81016-5. - DOI - PubMed

LinkOut - more resources